Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control studyBMJ 2002; 325 doi: https://doi.org/10.1136/bmj.325.7358.243 (Published 03 August 2002) Cite this as: BMJ 2002;325:243
- Carol E Koro, postgraduate ()a,
- Donald O Fedder, professorb,
- Gilbert J L'Italien, directorf,
- SheilaS Weiss, assistant professorb,
- LaurenceS Magder, associate professorc,
- Julie Kreyenbuhl, assistant professord,
- DennisA Revicki, chairman of boardg,
- RobertW Buchanan, professore
- aPharmaceutical Health Services Research Department, School of Pharmacy, University of Maryland, Baltimore, MD 21201, USA
- bPharmacy Practice and Science, University of Maryland
- cEpidemiology and Preventive Medicine, School of Medicine, University of Maryland
- dVA Capital Network Mental Illness Research, Education, and Clinical Center, University of Maryland
- eMaryland Psychiatric Research Center, University of Maryland
- fDecision Sciences Outcomes Research, Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492, USA
- gCenter for Health Outcomes Research, MEDTAP International, Bethesda, MD 20814, USA
- Correspondence to: C E Koro
- Accepted 28 February 2002
Objective: To quantify the association between olanzapine and diabetes.
Design: Population based nested case-control study.
Setting: United Kingdom based General Practice Research Database comprising 3.5 million patients followed between 1987 and 2000.
Participants: 19 637 patients who had been diagnosed as having and treated for schizophrenia. 451 incident cases of diabetes were matched with 2696 controls.
Main outcome measures: Diagnosis and treatment of diabetes.
Results: Patients taking olanzapine had a significantly increased risk of developing diabetes than non-users of antipsychotics (odds ratio 5.8, 95% confidence interval 2.0 to 16.7) and those taking conventional antipsychotics (4.2, 1.5 to 12.2). Patients taking risperidone had a non-significant increased risk of developing diabetes than non-users of antipsychotics (2.2, 0.9 to 5.2) and those taking conventional antipsychotics (1.6, 0.7 to 3.8).
Conclusion: Olanzapine is associated with a clinically important and significant increased risk of diabetes.
Funding Bristol-Myers Squibb provided the data from the General Practice Research Database for this study at no cost and without restriction.
Competing interests GJL is an employee of Bristol-Myers Squibb, Pharmaceutical Research Institute.